Cargando…

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML

PURPOSE: Hyperleukocytosis in AML with leukostasis is a serious life-threatening condition leading to a high early mortality which requires immediate cytoreductive therapy. Therapeutic leukapheresis is currently recommended by the American Society of Apheresis in patients with a WBC>100 G/l with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pastore, Friederike, Pastore, Alessandro, Wittmann, Georg, Hiddemann, Wolfgang, Spiekermann, Karsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986260/ https://www.ncbi.nlm.nih.gov/pubmed/24733550 http://dx.doi.org/10.1371/journal.pone.0095062

Ejemplares similares

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
por: Pastore, Friederike, et al.
Publicado: (2013)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome
por: Fraccaroli, Alessia, et al.
Publicado: (2023)

Therapeutic Leukapheresis: Experience of a Single Oncologic Centre
por: Rosales, Maria, et al.
Publicado: (2022)

Leukapheresis and Hyperleukocytosis, Past and Future
por: Zhang, Dongdong, et al.
Publicado: (2021)

Therapeutic leukapheresis in a tertiary care hospital: A case series
por: Makroo, Raj Nath, et al.
Publicado: (2017)

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
por: Janke, Hanna, et al.
Publicado: (2014)

Emergency therapeutic leukapheresis in a case of acute myeloid leukemia M5
por: Ranganathan, Sudha, et al.
Publicado: (2008)

Effect of leukapheresis on pain reduction in leukemic priapism
por: Noushad, Shahida, et al.
Publicado: (2022)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia – a single center analysis
por: Sandner, Anne-Sophie, et al.
Publicado: (2019)

Explainable AI identifies diagnostic cells of genetic AML subtypes
por: Hehr, Matthias, et al.
Publicado: (2023)

The factors influencing clinical outcomes after leukapheresis in acute leukaemia
por: Lee, Howon, et al.
Publicado: (2021)

Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
por: Jo, Tomoyasu, et al.
Publicado: (2023)

A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia
por: Jin, Yanxia, et al.
Publicado: (2018)

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML
por: Kempf, Julia M., et al.
Publicado: (2021)

Microenvironmental Hypoxia regulates FLT3 expression and biology in AML
por: Sironi, Silvia, et al.
Publicado: (2015)

Rapid Treatment of Leukostasis in Leukemic Mantle Cell Lymphoma using Therapeutic Leukapheresis: A Case Report
por: Nguyen, Xuan Duc, et al.
Publicado: (2011)

Pediatric acute lymphoblastic leukemia and leukapheresis: CT evidence of hemorrhagic complication
por: Suwita, Benedicta Mutiara, et al.
Publicado: (2020)

Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience
por: Jones, Sandra Renee, et al.
Publicado: (2022)

Whole blood viscosity issues VII: The correlation with leucocytosis and implication on leukapheresis
por: Nwose, Ezekiel Uba, et al.
Publicado: (2010)

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study
por: Stahl, Maximilian, et al.
Publicado: (2020)

Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
por: Batcha, Aarif M. N., et al.
Publicado: (2022)

Acute vision loss due to CML leukemic retinopathy reversed with leukapheresis
por: Leong, Sally, et al.
Publicado: (2023)

Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
por: Farina, Mirko, et al.
Publicado: (2022)

Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing
por: Noaks, Elsa, et al.
Publicado: (2021)

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
por: Haubner, S., et al.
Publicado: (2018)

T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy
por: Wada, Fumiya, et al.
Publicado: (2022)

Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity
por: Witter, Klaus, et al.
Publicado: (2014)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Von AML bis Zytokinfreisetzung
por: Klein, Friederike
Publicado: (2022)

The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia—Case report and review of literature
por: van der Velde, Marleen G. A. M., et al.
Publicado: (2022)

Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
por: Dreger, P., et al.
Publicado: (1993)

Age-Related Disease Association of Endogenous γ-H2AX Foci in Mononuclear Cells Derived from Leukapheresis
por: Schurman, Shepherd H., et al.
Publicado: (2012)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

P55. Dendritic cell vaccination for postremission therapy in AML
por: Lichtenegger, FS, et al.
Publicado: (2014)

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
por: Schnorfeil, Frauke M., et al.
Publicado: (2015)

Optimal large‐scale CD34+ enrichment from a leukapheresis collection using the clinimacs prodigy platform
por: Pello, Oscar M., et al.
Publicado: (2020)

RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients
por: Dong, Liang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mv4b3n82i9p4r45rvanms8dl2l